US 10683354
Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells
granted A61KA61K2039/505A61K31/537
Quick answer
US patent 10683354 (Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cells) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61K31/537, A61K47/68031, A61K47/68033